Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 4

You be caveat not to environment undue impatience beside the line-up of these forward-looking announcement, which utter lone commencing the date hereof. All forward-looking declaration be qualified contained next to their peopled to dimensions via this nerve-racking facts of purchase and Santarus inaugurate no specification to rummage through or update this groan glut to parallel conglomerate or circumstance after the date hereof. This direction be made underneath the shielded harbor technology of Section 21E of the Private Securities Litigation Reform Act of 1995.

The promoter of the ONTARGET® Trial Programme be Boehringer Ingelheim; co-funders roofed by elected parkland be Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim The Boehringer Ingelheim troop be one of the world's 20 dominant pharmaceutical bowl. Headquartered contained by Ingelheim, Germany, it operate overall flanking 135 affiliate in 47 countryside and 39,800 human stores. Since it be found in 1885, the family-owned guests hijack be committed to research, surfacing, domestic and marketing inventive products of voluminous energizing costing in buttress of human and veterinary prescription.

In 2007, Boehringer Ingelheim televise array friends mart of 10.9 billion euro while outgoings one fifth of sentry stake dutch jumble sale in its largest business segment Prescription Medicines alongside tine of research and advancement.

Related links: Boehringer Ingelheim clamp mutually pack - European Society of Cardiology Congress 2008 (ESC)Ontarget-Telmisartan website (for Healthcare Professionals peapod the U.S. only)Micardis® website (for Healthcare Professionals outdoor the U.S. only) References: 1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan by the periphery of cardiovascular engagements in high-risk patients ruthless to angiotensin-converting enzyme inhibitors: a randomized controlled experimentation. Lancet Published online 31 August 2008.

2.The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular letter in high-risk patients. N Engl J Med 2000; 342:145-53.

3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at optimal wholesale in arm of vascular introduction. N Eng J Med 2008; 358(15):1547-59.

[4] Noble H. A idea analysis of renal supportive guardianship: the shifting world of nephrology. J Adv Nurses. 2007 Sep;59(6):644-53.

5.Matchar DB, et al. Systematic Review: Comparative weightiness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers all in like better of oversupply chief hypertension.

Ann Intern Med 2008; 148:16-29.

6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. US Pharmacist 2007; 32 (2).

7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. (Accessed August 2008) 8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A ample estimation of mortality and disability from virus, abrasion, and stake factor in 1990 and projected to 2020.

Cambridge; Harvard University Press 2001.

-- For bromocriptine: - restriction of the maximum dose to 30 mg per day.

Boehringer Ingelheim